Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$404 Mln
P/E Ratio
--
P/B Ratio
6.52
Industry P/E
--
Debt to Equity
0.01
ROE
-0.78 %
ROCE
-73.09 %
Div. Yield
0 %
Book Value
0.41
EPS
-0.29
CFO
$-228.85 Mln
EBITDA
$-279.13 Mln
Net Profit
$-360.82 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| -28.00 | 9.57 | -12.20 | -8.03 | 55.64 | 16.00 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| 51.00 | 208.00 | -53.13 | -55.31 | 9.15 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,315.11 | 21.27 | 23.13 | |
| 306.35 | 8,705.27 | 22.77 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an... antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. Address: One Cavendish Place, London, United Kingdom, W1G 0QF Read more
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mereo BioPharma Group plc - ADR stood at $ 76 Mln as on 31-Dec-24
The share price of Mereo BioPharma Group plc - ADR is $2.52 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Mereo BioPharma Group plc - ADR has given a return of 55.64% in the last 3 years.
Mereo BioPharma Group plc - ADR has a market capitalisation of $ 404 Mln as on 28-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Mereo BioPharma Group plc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mereo BioPharma Group plc - ADR and enter the required number of quantities and click on buy to purchase the shares of Mereo BioPharma Group plc - ADR.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. Address: One Cavendish Place, London, United Kingdom, W1G 0QF
The CEO & director of Dr. Denise Vera Scots-Knight Ph.D.. is Mereo BioPharma Group plc - ADR, and CFO & Sr. VP is Dr. Denise Vera Scots-Knight Ph.D..
There is no promoter pledging in Mereo BioPharma Group plc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Mereo BioPharma Group plc - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-77.58
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mereo BioPharma Group plc - ADR was $0 Mln.
$-0.09
(
